Targeting tumor cells with antibodies enhances anti-tumor immunity
Tumor-targeting antibodies were initially defined as a group of therapeutic monoclonal antibodies (mAb) that recognize tumor-specific membrane proteins, block cell signaling, and induce tumor-killing through Fc-driven innate immune responses. However, in the past decade, ample evidence has shown tha...
Gespeichert in:
| Veröffentlicht in: | Biophysics reports 2018, Vol.4 (5), p.243-253 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 253 |
|---|---|
| container_issue | 5 |
| container_start_page | 243 |
| container_title | Biophysics reports |
| container_volume | 4 |
| creator | Sun, Zhichen Fu, Yang-Xin Peng, Hua |
| description | Tumor-targeting antibodies were initially defined as a group of therapeutic monoclonal antibodies (mAb) that recognize tumor-specific membrane proteins, block cell signaling, and induce tumor-killing through Fc-driven innate immune responses. However, in the past decade, ample evidence has shown that tumor-targeting mAb (TTmAb) eradicates tumor cells via activation of cytotoxic T cells (CTLs). In this review, we specifically focus on how TTmAbs induce adaptive anti-tumor immunity and its potential in combination therapy with immune cytokines, checkpoint blockade, radiation, and enzyme-targeted small molecule drugs. Exploring the mechanisms of these preclinical studies and retrospective clinical data will significantly benefit the development of highly efficient and specific TTmAb-oriented anti-tumor remedies. |
| doi_str_mv | 10.1007/s41048-018-0070-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6245233</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2772579942</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3432-fd43222eba50b9e516f9b802fae343402ef18f7220c8aeb6fd02a14f505baaa43</originalsourceid><addsrcrecordid>eNp9UctOwzAQtBCIotIP4IIicQ6s187rggQVL6kSl3K2nNRujRqn2Amof4-jlAIHOHi92hmPxx5CzihcUoDsynMKPI-BhgUZxHhATpClPGYc4XDfs2JEJt6bEjjPGE1TekxGDBLGeF6ckNu5dEvVGruM2q5uXFSp9dpHH6ZdRdK2pmwWRvlI2ZW0VWj6WTwwTV131rTbU3Kk5dqryW4fk5f7u_n0MZ49PzxNb2ZxFVxgrBehIqpSJlAWKqGpLsocUEsVcA6oNM11hghVLlWZ6gWgpFwnkJRSSs7G5HrQ3XRlrRaVsq2Ta7FxppZuKxppxG_EmpVYNu8iRZ4gY0HgYifgmrdO-Va8Np2zwbPALMMkKwqO_7I4hP9M06Q3QwdW5RrvndJ7HxREn48Y8hEhH9HnI3rl858P2J_4SiMQcCD4ANmlct9X_636CcTrmy8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2404396654</pqid></control><display><type>article</type><title>Targeting tumor cells with antibodies enhances anti-tumor immunity</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Springer Nature OA Free Journals</source><creator>Sun, Zhichen ; Fu, Yang-Xin ; Peng, Hua</creator><creatorcontrib>Sun, Zhichen ; Fu, Yang-Xin ; Peng, Hua</creatorcontrib><description>Tumor-targeting antibodies were initially defined as a group of therapeutic monoclonal antibodies (mAb) that recognize tumor-specific membrane proteins, block cell signaling, and induce tumor-killing through Fc-driven innate immune responses. However, in the past decade, ample evidence has shown that tumor-targeting mAb (TTmAb) eradicates tumor cells via activation of cytotoxic T cells (CTLs). In this review, we specifically focus on how TTmAbs induce adaptive anti-tumor immunity and its potential in combination therapy with immune cytokines, checkpoint blockade, radiation, and enzyme-targeted small molecule drugs. Exploring the mechanisms of these preclinical studies and retrospective clinical data will significantly benefit the development of highly efficient and specific TTmAb-oriented anti-tumor remedies.</description><identifier>ISSN: 2364-3439</identifier><identifier>EISSN: 2364-3420</identifier><identifier>DOI: 10.1007/s41048-018-0070-2</identifier><identifier>PMID: 30533489</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adaptive immunity ; Antibodies ; Antigens ; Apoptosis ; Biochemistry ; Biological and Medical Physics ; Biomedical and Life Sciences ; Biophysics ; Biotechnology ; Breast cancer ; Cell activation ; Cell cycle ; Cell signaling ; Cytokines ; Cytotoxicity ; Epidermal growth factor ; FDA approval ; Immune checkpoint ; Immune checkpoint inhibitors ; Immunity ; Immunosuppressive agents ; Innate immunity ; Kinases ; Life Sciences ; Ligands ; Lymphocytes ; Lymphocytes T ; Lymphoma ; Membrane proteins ; Monoclonal antibodies ; Radiation ; Review ; Roles ; Tumor cells</subject><ispartof>Biophysics reports, 2018, Vol.4 (5), p.243-253</ispartof><rights>The Author(s) 2018</rights><rights>The Author(s) 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2018. This article is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3432-fd43222eba50b9e516f9b802fae343402ef18f7220c8aeb6fd02a14f505baaa43</citedby><cites>FETCH-LOGICAL-c3432-fd43222eba50b9e516f9b802fae343402ef18f7220c8aeb6fd02a14f505baaa43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s41048-018-0070-2$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://doi.org/10.1007/s41048-018-0070-2$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,860,881,27901,27902,41096,42165,51551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30533489$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sun, Zhichen</creatorcontrib><creatorcontrib>Fu, Yang-Xin</creatorcontrib><creatorcontrib>Peng, Hua</creatorcontrib><title>Targeting tumor cells with antibodies enhances anti-tumor immunity</title><title>Biophysics reports</title><addtitle>Biophys Rep</addtitle><addtitle>Biophys Rep</addtitle><description>Tumor-targeting antibodies were initially defined as a group of therapeutic monoclonal antibodies (mAb) that recognize tumor-specific membrane proteins, block cell signaling, and induce tumor-killing through Fc-driven innate immune responses. However, in the past decade, ample evidence has shown that tumor-targeting mAb (TTmAb) eradicates tumor cells via activation of cytotoxic T cells (CTLs). In this review, we specifically focus on how TTmAbs induce adaptive anti-tumor immunity and its potential in combination therapy with immune cytokines, checkpoint blockade, radiation, and enzyme-targeted small molecule drugs. Exploring the mechanisms of these preclinical studies and retrospective clinical data will significantly benefit the development of highly efficient and specific TTmAb-oriented anti-tumor remedies.</description><subject>Adaptive immunity</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Apoptosis</subject><subject>Biochemistry</subject><subject>Biological and Medical Physics</subject><subject>Biomedical and Life Sciences</subject><subject>Biophysics</subject><subject>Biotechnology</subject><subject>Breast cancer</subject><subject>Cell activation</subject><subject>Cell cycle</subject><subject>Cell signaling</subject><subject>Cytokines</subject><subject>Cytotoxicity</subject><subject>Epidermal growth factor</subject><subject>FDA approval</subject><subject>Immune checkpoint</subject><subject>Immune checkpoint inhibitors</subject><subject>Immunity</subject><subject>Immunosuppressive agents</subject><subject>Innate immunity</subject><subject>Kinases</subject><subject>Life Sciences</subject><subject>Ligands</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Lymphoma</subject><subject>Membrane proteins</subject><subject>Monoclonal antibodies</subject><subject>Radiation</subject><subject>Review</subject><subject>Roles</subject><subject>Tumor cells</subject><issn>2364-3439</issn><issn>2364-3420</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>BENPR</sourceid><recordid>eNp9UctOwzAQtBCIotIP4IIicQ6s187rggQVL6kSl3K2nNRujRqn2Amof4-jlAIHOHi92hmPxx5CzihcUoDsynMKPI-BhgUZxHhATpClPGYc4XDfs2JEJt6bEjjPGE1TekxGDBLGeF6ckNu5dEvVGruM2q5uXFSp9dpHH6ZdRdK2pmwWRvlI2ZW0VWj6WTwwTV131rTbU3Kk5dqryW4fk5f7u_n0MZ49PzxNb2ZxFVxgrBehIqpSJlAWKqGpLsocUEsVcA6oNM11hghVLlWZ6gWgpFwnkJRSSs7G5HrQ3XRlrRaVsq2Ta7FxppZuKxppxG_EmpVYNu8iRZ4gY0HgYifgmrdO-Va8Np2zwbPALMMkKwqO_7I4hP9M06Q3QwdW5RrvndJ7HxREn48Y8hEhH9HnI3rl858P2J_4SiMQcCD4ANmlct9X_636CcTrmy8</recordid><startdate>2018</startdate><enddate>2018</enddate><creator>Sun, Zhichen</creator><creator>Fu, Yang-Xin</creator><creator>Peng, Hua</creator><general>Springer Berlin Heidelberg</general><general>Institute of Biophysics</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>2018</creationdate><title>Targeting tumor cells with antibodies enhances anti-tumor immunity</title><author>Sun, Zhichen ; Fu, Yang-Xin ; Peng, Hua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3432-fd43222eba50b9e516f9b802fae343402ef18f7220c8aeb6fd02a14f505baaa43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adaptive immunity</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Apoptosis</topic><topic>Biochemistry</topic><topic>Biological and Medical Physics</topic><topic>Biomedical and Life Sciences</topic><topic>Biophysics</topic><topic>Biotechnology</topic><topic>Breast cancer</topic><topic>Cell activation</topic><topic>Cell cycle</topic><topic>Cell signaling</topic><topic>Cytokines</topic><topic>Cytotoxicity</topic><topic>Epidermal growth factor</topic><topic>FDA approval</topic><topic>Immune checkpoint</topic><topic>Immune checkpoint inhibitors</topic><topic>Immunity</topic><topic>Immunosuppressive agents</topic><topic>Innate immunity</topic><topic>Kinases</topic><topic>Life Sciences</topic><topic>Ligands</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Lymphoma</topic><topic>Membrane proteins</topic><topic>Monoclonal antibodies</topic><topic>Radiation</topic><topic>Review</topic><topic>Roles</topic><topic>Tumor cells</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sun, Zhichen</creatorcontrib><creatorcontrib>Fu, Yang-Xin</creatorcontrib><creatorcontrib>Peng, Hua</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Biophysics reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sun, Zhichen</au><au>Fu, Yang-Xin</au><au>Peng, Hua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting tumor cells with antibodies enhances anti-tumor immunity</atitle><jtitle>Biophysics reports</jtitle><stitle>Biophys Rep</stitle><addtitle>Biophys Rep</addtitle><date>2018</date><risdate>2018</risdate><volume>4</volume><issue>5</issue><spage>243</spage><epage>253</epage><pages>243-253</pages><issn>2364-3439</issn><eissn>2364-3420</eissn><abstract>Tumor-targeting antibodies were initially defined as a group of therapeutic monoclonal antibodies (mAb) that recognize tumor-specific membrane proteins, block cell signaling, and induce tumor-killing through Fc-driven innate immune responses. However, in the past decade, ample evidence has shown that tumor-targeting mAb (TTmAb) eradicates tumor cells via activation of cytotoxic T cells (CTLs). In this review, we specifically focus on how TTmAbs induce adaptive anti-tumor immunity and its potential in combination therapy with immune cytokines, checkpoint blockade, radiation, and enzyme-targeted small molecule drugs. Exploring the mechanisms of these preclinical studies and retrospective clinical data will significantly benefit the development of highly efficient and specific TTmAb-oriented anti-tumor remedies.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>30533489</pmid><doi>10.1007/s41048-018-0070-2</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2364-3439 |
| ispartof | Biophysics reports, 2018, Vol.4 (5), p.243-253 |
| issn | 2364-3439 2364-3420 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6245233 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Springer Nature OA Free Journals |
| subjects | Adaptive immunity Antibodies Antigens Apoptosis Biochemistry Biological and Medical Physics Biomedical and Life Sciences Biophysics Biotechnology Breast cancer Cell activation Cell cycle Cell signaling Cytokines Cytotoxicity Epidermal growth factor FDA approval Immune checkpoint Immune checkpoint inhibitors Immunity Immunosuppressive agents Innate immunity Kinases Life Sciences Ligands Lymphocytes Lymphocytes T Lymphoma Membrane proteins Monoclonal antibodies Radiation Review Roles Tumor cells |
| title | Targeting tumor cells with antibodies enhances anti-tumor immunity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T18%3A49%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20tumor%20cells%20with%20antibodies%20enhances%20anti-tumor%20immunity&rft.jtitle=Biophysics%20reports&rft.au=Sun,%20Zhichen&rft.date=2018&rft.volume=4&rft.issue=5&rft.spage=243&rft.epage=253&rft.pages=243-253&rft.issn=2364-3439&rft.eissn=2364-3420&rft_id=info:doi/10.1007/s41048-018-0070-2&rft_dat=%3Cproquest_pubme%3E2772579942%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2404396654&rft_id=info:pmid/30533489&rfr_iscdi=true |